|
| WHI-P97 Basic information |
Product Name: | WHI-P97 | Synonyms: | WHI-P 974-(3',5'-DibroMo-4-hydroxyphenyl)aMino-6,7-diMethoxyquinazoline;2,6-dibromo-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol;JAK3 Inhibitor I USP/EP/BP;Phenol, 2,6-dibromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]-;WHI-P-97;WHI P97;WHI-P97;Janus kinase,JAK,airway,Inhibitor,WHIP97,eosinophil recruitment,WHI-P97,inhibit,ovalbumin challenge,WHI P97,ovalbumin-sensitized,WHI-P-97 | CAS: | 211555-05-4 | MF: | C16H13Br2N3O3 | MW: | 455.1 | EINECS: | | Product Categories: | | Mol File: | 211555-05-4.mol | |
| WHI-P97 Chemical Properties |
Boiling point | 470.9±45.0 °C(Predicted) | density | 1.785 | storage temp. | Store at -20°C | solubility | DMSO : 5.88 mg/mL (12.92 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble) | form | Powder | pka | 7.05±0.36(Predicted) | color | White to gray |
| WHI-P97 Usage And Synthesis |
Definition | ChEBI: 2,6-dibromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenol is a member of quinazolines. | Biological Activity | WHI-P97 is a potent JAK-3 inhibitor with Ki of 0.09 μM and IC50 of 2.5 μM in EGFR kinase inhibition assay. | in vitro | WHI-P97 inhibits the translocation of 5-lipoxygenase (5-LO) from the nucleoplasm to the nuclear membrane and consequently 5-LO-dependent leukotriene (LT) synthesis after IgE receptor/FcεRI crosslinking by >90 % at low micromolar concentrations. WHI-P97 (30 μM) stantially reduces the IgE/antigen-induced LTC4 release from mast cells. | in vivo | WHI-P97 is very well tolerated in mice, with no signs of toxicity at dose levels ranging from 5 μg/kg to 50 mg/kg, and LD 10 is not reached at a 50 mg/kg dose level when administered as a single ip or iv bolus dose. WHI-P97 (iv injection; 40 mg/kg; single dose) has an elimination half-life (t 1/2 ) of 58.9 min and systemic clearance (CL) of 891 ml/h/kg in CD-1 mice and at 1/2 of 84.2 min and CL of 1513 ml/h/kg in BALB/ c mice. The values for AUC and C max are 107.3 μM and 296.7 μM, respectively, in CD-1 mice. And the IC 50 values are 58.4 μM and 212.7 μM , respectively, in BALB/c mice. The large volume of distribution are 322 ml/kg in CD-1 mice and 415 ml/kg in BALB/c mice. WHI-P97 (intraperitoneal injection; 40 mg/kg; 24 days) prevents ovalbumin-sensitized mice the development of airway hyper-responsiveness to methacholine in a dose-dependent fashion in mice. WHI-P97 inhibits the eosinophil recruitment to the airwa y lumen after the ovalbumin challenge in a dose-dependent fashion. Animal Model: | BALB/c mouse model of allergic asthma td> | Dosage: | 40 mg/kg | Administration: | intraperitoneal injection; 24 days | Result: | Showed promising biological activity in a mouse model of allergic asthma at nontoxic dose levels. | | target | Target | Value | JAK3 () | table>
| WHI-P97 Preparation Products And Raw materials |
|
Tag:WHI-P97(211555-05-4)
Related Product Information
|
JAK3 INHIBITOR I
4-(3'-HYDROXYPHENYL)AMINO-6,7-DIMETHOXYQUINAZOLINE, HCL
3'-Hydroxyacetophenone
Dihydroxybenzoic acid
2-HYDROXYACETOPHENONE
4-PHENYLAMINO-6,7-DIMETHOXYQUINAZOLINE
JAK3 Inhibitor
Phenol, 3-[(6,7-diMethoxy-4-quinazolinyl)aMino]-
|
According to the laws, regulations and policies related to "patent products", the sale of this product is prohibited!
ChemicalBook prompt
The patent owner or licensee of the product has not released any relevant information for the time being.
|